However, cDCs in the PI3K/mTORi+PD‐1i‐treated tumours upregulated expression of genes related to antigen presentation via major histocompatibility complex class II (MHC II) (HLA‐DRB1, HLA‐DQB1, HLA‐DPB1, HLA‐DQB2, CD74) compared with cDCs in tumours treated with PD‐1i, PI3K/mTORi‐ or vehicle (Figure S5A). The gene discussed is PIK3CB; the disease is neoplasm.